Modular Medical Receives Research Demonstrating Positive Payor Reception of Pivot Tubeless Patch Pump
Rhea-AI Summary
Modular Medical (NASDAQ: MODD) reported results from an independent market research study on its FDA-cleared Pivot tubeless patch pump. The research found positive payor receptivity driven by Pivot’s differentiated, simple modular design, tubeless and reusable architecture, 300 IU reservoir, and one-button operation.
According to Modular Medical, payors viewed Pivot favorably for potential reimbursement through pharmacy benefit channels, citing alignment of its disposable component structure and anticipated contracting strategy with existing frameworks. Respondents also indicated interest in strategic partnership models with large healthcare organizations to support broader patient access, evidence generation, and long-term adoption of simplified insulin delivery solutions.
Positive
- None.
Negative
- None.
News Market Reaction – MODD
On the day this news was published, MODD declined 2.78%, reflecting a moderate negative market reaction. Argus tracked a peak move of +6.6% during that session. Argus tracked a trough of -31.9% from its starting point during tracking. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $667K from the company's valuation, bringing the market cap to $23.33M at that time. Trading volume was elevated at 2.1x the daily average, suggesting increased selling activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 14 | market research | Positive | +9.8% | Patient research showed strong interest in simpler insulin pump therapy. |
| Jul 01 | regulatory update | Positive | +4.0% | FDA submission of software enhancements for Pivot insulin patch pump. |
| Jun 30 | commercial rollout | Positive | -7.8% | First patients trained and using Pivot pump in real-world settings. |
| Jun 26 | product shipment | Positive | +19.9% | Pivot starter kits shipping to endocrinology practices for training. |
| Jun 24 | commercial launch | Positive | -2.2% | U.S. commercial availability of Pivot after FDA 510(k) clearance. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent Pivot-related updates have often moved the stock sharply, with a slight tilt toward positive alignment but notable negative divergences on good news.
Key Terms
tubeless patch pump technical
reimbursement financial
pharmacy channel financial
market access financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Completed Independent Study Strongly Supports Favorable Payor Receptivity to Pivot's Differentiated Design and Simplified User Experience, and provides further validation of significant progress towards goal of achieving broad market access for Pivot
SAN DIEGO, CA / ACCESS Newswire / July 15, 2026 / Modular Medical, Inc. ("Modular Medical" or "the Company") (NASDAQ:MODD), a commercial-stage medical device company that is commercializing the next generation of insulin delivery technology, today released findings from an independent market research study demonstrating positive receptivity to its FDA-cleared Pivot™ tubeless patch pump due to its differentiated design, streamlined user experience, and potential for reimbursement through the pharmacy channel.
"From the earliest stages of development, our goal has been to develop a practical and affordable insulin pumping solution that removes many of the barriers preventing insulin-dependent individuals from transitioning from multiple daily injections to pump therapy," said Jeb Besser, CEO of Modular Medical. "The positive feedback from this market access assessment provides significant third-party validation of our commercialization strategy and reinforces Pivot's differentiated value proposition with key payor stakeholders."
As part of its commercialization strategy, the Company partnered with an independent organization specializing in the assessment of market viability, payor access, and commercialization strategies for therapeutic products. The firm specializes in supporting product launches, pricing assessments, reimbursement strategy, and go-to-market planning for life science companies. The objective of the engagement was to better understand payor receptivity, reimbursement considerations, and market positioning opportunities for the Pivot tubeless patch pump.
Strong Recognition on Product Differentiation
The research indicated that payors viewed the Pivot tubeless patch pump as a differentiated offering within the insulin pump landscape. Respondents identified the system's simple modular design, tubeless and reusable architecture, 300 international unit (IU) reservoir capacity, and intuitive one-button functionality as features that addressed unmet needs among insulin-dependent individuals seeking a less complex insulin delivery experience.
These findings reinforce the Company's belief that a significant opportunity exists to expand insulin pump adoption by reducing complexity and improving accessibility for a broader population of insulin-dependent people.
Favorable Reimbursement Perspectives
The assessment also explored potential reimbursement and coverage considerations. Feedback indicated that several payor organizations viewed Pivot favorably from a market access perspective, noting that its disposable component structure and anticipated contracting strategy align well with existing pharmacy benefit frameworks.
Strategic Partnership Opportunities
Beyond payor access considerations, the research also explored potential opportunities for strategic collaboration with large healthcare organizations. Respondents expressed strong interest in innovative partnership models that support broader patient access, evidence generation, and long-term adoption of simplified insulin delivery solutions.
About Modular Medical, Inc.
Modular Medical, Inc. (NASDAQ:MODD) is a commercial-stage medical device company focused on the development of innovative insulin delivery technologies designed to simplify diabetes management and increase access to insulin pump therapy. The Company's Pivot™ Tubeless Patch Pump has been developed to provide a user-friendly, flexible, and accessible approach to insulin delivery for people requiring intensive insulin therapy.
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statements contained in this press release, including but not limited to, the Company's ability to convert patients to use its Pivot pump product, the Company's ability to obtain payor reimbursement for its products, successful development of Modular Medical's proprietary technologies, whether the market will accept Modular Medical's products and services, anticipated consumer demand for the Company's products, whether Modular Medical can successfully manufacture its products at high volumes, and general economic, and industry or political conditions in the United States or internationally, as well as other risk factors and business considerations described in Modular Medical's SEC filings, including its annual report on Form 10-K. Any forward-looking statements in this press release should be evaluated in light of these important risk factors. In addition, any forward-looking statements included in this press release represent Modular Medical's views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. Modular Medical assumes no obligation to update these forward-looking statements, except as required by law.
Company Contact:
Jeb Besser
Chief Executive Officer
Modular Medical, Inc.
IR@modular-medical.com
Investor Relations Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
ModularMedical@KSCA.com
SOURCE: Modular Medical, Inc.
View the original press release on ACCESS Newswire